Diffusion weighted MR imaging in patients with HCC and liver cirrhosis after administration of different gadolinium contrast agents: Is it still reliable?

Kinner, Sonja; Umutlu, Lale; Blex, Sebastian; Maderwald, Stefan; Antoch, Gerald; Ertle, Judith; Gerken, Guido; Lauenstein, Thomas C.

doi:10.1016/j.ejrad.2011.12.042

Cited by 18 publications

(11 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chiu et al found that gadoxetic acid administration does not compromise CNR and ADC of focal hepatic lesions, while Choi et al have shown that DWI after gadoxetic acid administration can be used as a substitute for unenhanced DWI without compromising the CNR and ADC of focal hepatic lesions. Kinner et al did not observe a significant difference regarding DWI in patients with cirrhosis before and after CA injection.…”

Section: Discussionmentioning

confidence: 90%

Effects of gadoxetic acid on quantitative diffusion‐weighted imaging of the liver

Colagrande

Mazzoni

et al. 2012

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 90%

Effects of gadoxetic acid on quantitative diffusion‐weighted imaging of the liver

Colagrande

Mazzoni

et al. 2012

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…DWI performed postgadolinium administration has been shown to have a similar appearance to DWI performed pregadolinium in the prostate, liver, spleen, pancreas, and kidney .…”

Section: Background Considerations For Clinical Whole‐body Diffusionmentioning

confidence: 86%

Whole body MRI: Improved lesion detection and characterization with diffusion weighted techniques

Attariwala

Picker

2013

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Diffusion-weighted imaging (DWI) is an established functional imaging technique that interrogates the delicate balance of water movement at the cellular level. Technological advances enable this technique to be applied to whole-body MRI. Theory, b-value selection, common artifacts and target to background for optimized viewing will be reviewed for applications in the neck, chest, abdomen, and pelvis. Whole-body imaging with DWI allows novel applications of MRI to aid in evaluation of conditions such as multiple myeloma, lymphoma, and skeletal metastases, while the quantitative nature of this technique permits evaluation of response to therapy. Persisting signal at high b-values from restricted hypercellular tissue and viscous fluid also permits applications of DWI beyond oncologic imaging. DWI, when used in conjunction with routine imaging, can assist in detecting hemorrhagic degradation products, infection/abscess, and inflammation in colitis, while aiding with discrimination of free fluid and empyema, while limiting the need for intravenous contrast. DWI in conjunction with routine anatomic images provides a platform to improve lesion detection and characterization with findings rivaling other combined anatomic and functional imaging techniques, with the added benefit of no ionizing radiation.

show abstract

“…It has actually become common to encounter cases where hypervascular HCC or nodule-in-nodule HCC that is undetectable by MDCT is detected in a routine screening by EOB-MRI because of early enhancement in the arterial phase or clear hypointensity in the hepatobiliary phase [11,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103]. Furthermore, studies comparing the diagnostic performance of EOB-MRI and MDCT for hypervascular HCC have shown that EOB-MRI is superior or, at the very l...…”

Section: Diagnostic Algorithmmentioning

confidence: 99%

Surveillance and Diagnostic Algorithm for Hepatocellular Carcinoma Proposed by the Liver Cancer Study Group of Japan: 2014 Update

et al. 2014

View full text Add to dashboard Cite

Surveillance and diagnostic algorithms for hepatocellular carcinoma (HCC) have already been described in guidelines published by the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver and the European Organisation for Research and Treatment of Cancer (EASL-EORTC), and the Japan Society of Hepatology (JSH), but the content of these algorithms differs slightly. The JSH algorithm mainly differs from the other two algorithms in that it is highly sophisticated and considers the functional imaging techniques of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced MRI (EOB-MRI) and Sonazoid contrast-enhanced ultrasound (CEUS) to be very important diagnostic modalities. In contrast, the AASLD and EASL-EORTC algorithms are less advanced and suggest that a diagnosis be made based solely on hemodynamic findings using dynamic CT/MRI and biopsy findings. A consensus meeting regarding the JSH surveillance and diagnostic algorithm was held at the 50th Liver Cancer Study Group of Japan Congress, and a 2014 update of the algorithm was completed. The new algorithm reaffirms the very important role of EOB-MRI and Sonazoid CEUS in the surveillance and diagnosis of liver cancer and is more sophisticated than those currently used in the United States and Europe. This is now an optimized algorithm that can be used to diagnose early-stage to classical HCC easily and highly accurately.

show abstract

Diffusion weighted MR imaging in patients with HCC and liver cirrhosis after administration of different gadolinium contrast agents: Is it still reliable?

Cited by 18 publications

References 15 publications

Effects of gadoxetic acid on quantitative diffusion‐weighted imaging of the liver

Effects of gadoxetic acid on quantitative diffusion‐weighted imaging of the liver

Whole body MRI: Improved lesion detection and characterization with diffusion weighted techniques

Surveillance and Diagnostic Algorithm for Hepatocellular Carcinoma Proposed by the Liver Cancer Study Group of Japan: 2014 Update

Contact Info

Product

Resources

About